{
    "clinical_study": {
        "@rank": "48767", 
        "arm_group": {
            "arm_group_label": "dupilumab treatment", 
            "arm_group_type": "Experimental", 
            "description": "dupilumab loading dose (Dose 1x2),  followed by Dose 1 every 2 weeks  in combination with fluticasone propionate and salmeterol, or budesonide and formoterol, or mometasone furoate and formoterol."
        }, 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      Evaluate the long-term safety and tolerability of dupilumab in patients with asthma who\n      participated in a previous dupilumab asthma study; ie DRI12544.\n\n      Secondary Objectives:\n\n      Evaluate the efficacy of dupilumab in patients with asthma who participated in a previous\n      dupilumab asthma clinical study.\n\n      Evaluate dupilumab in patients with asthma who participated in a previous dupilumab asthma\n      clinical study, with regard to:\n\n        -  Systemic exposure\n\n        -  Anti-drug antibodies\n\n        -  Biomarkers"
        }, 
        "brief_title": "Long-Term Safety Evaluation of Dupilumab in Patients With Asthma", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "The total duration of study participation includes a screening period of up to 3 weeks\n      (drug-free), followed by an open-label treatment period of 96 weeks and a 16-week\n      post-treatment period (drug-free)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Eligible patients who have completed a previous dupilumab asthma study (ie,\n             DRI12544).\n\n        Exclusion criteria:\n\n          -  Patients who did not complete the previous dupilumab asthma study (entire study\n             duration).\n\n          -  Patients who have experienced hypersensitivity reactions to dupilumab.\n\n          -  Patients diagnosed with active parasitic infection; suspected or at high risk of\n             parasitic infection, unless clinical and/or laboratory assessments before\n             randomization have ruled out an active infection.\n\n          -  Medical history of human immunodeficiency virus (HIV) infection.\n\n          -  Known or suspected medical history of immunosuppression, including history of\n             invasive opportunistic infections (eg, tuberculosis, histoplasmosis, listeriosis,\n             coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution; or\n             unusually frequent, recurrent or prolonged infections, as per investigator judgment.\n\n          -  Evidence of acute or chronic infection requiring treatment with antibacterials,\n             antivirals, antifungals, antiparasitics or antiprotozoals within 4 weeks before Visit\n             1; significant viral infections within 4 weeks before Visit 1 that may not have\n             received antiviral treatment (eg, influenza receiving only symptomatic treatment).\n\n          -  Patients with any event or laboratory abnormality that, as per investigator judgment,\n             would adversely affect participation of the patient in this study.\n\n          -  Patients who have traveled to parasitic endemic area within 6 months prior to\n             screening.\n\n          -  The above information is not intended to contain all considerations relevant to a\n             patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "560", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02134028", 
            "org_study_id": "LTS12551", 
            "secondary_id": [
                "2013-003856-19", 
                "U1111-1117-6745"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "dupilumab treatment", 
                "description": "Pharmaceutical form:solution Route of administration: subcutaneous", 
                "intervention_name": "dupilumab SAR231893 (REGN668)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "dupilumab treatment", 
                "description": "Pharmaceutical form:aerosol Route of administration: inhalation", 
                "intervention_name": "fluticasone propionate and salmeterol", 
                "intervention_type": "Drug", 
                "other_name": "Advair\u00ae/Seretide\u00ae"
            }, 
            {
                "arm_group_label": "dupilumab treatment", 
                "description": "Pharmaceutical form:aerosol Route of administration: inhalation", 
                "intervention_name": "budesonide and formoterol", 
                "intervention_type": "Drug", 
                "other_name": "Symbicort\u00ae"
            }, 
            {
                "arm_group_label": "dupilumab treatment", 
                "description": "Pharmaceutical form:aerosol Route of administration: inhalation", 
                "intervention_name": "mometasone furoate and formoterol", 
                "intervention_type": "Drug", 
                "other_name": "Dulera\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Budesonide", 
                "Formoterol", 
                "Salmeterol", 
                "Fluticasone", 
                "Mometasone furoate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 6, 2014", 
        "number_of_arms": "1", 
        "official_title": "Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in Previous Dupilumab Asthma Clinical Study", 
        "overall_contact": {
            "email": "Contact-US@sanofi.com", 
            "last_name": "Trial Transparency Team"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Australia: Human Research Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Week 112"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02134028"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assessment of safety parameters (laboratory data, electrocardiogram and vital signs) - clinically significant changes from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 112"
            }, 
            {
                "measure": "Forced expiratory volume in one second - clinically significant changes from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 112"
            }, 
            {
                "measure": "Asthma control questionnaire - clinically significant changes from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 112"
            }, 
            {
                "measure": "Asthma symptom scores - clinically significant changes from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 112"
            }, 
            {
                "measure": "Asthma Quality of Life Questionnaire (AQLQS) - clinically significant changes from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 112"
            }, 
            {
                "measure": "Anti-drug antibodies - changes from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 112"
            }, 
            {
                "measure": "Biomarkers - changes from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 96"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "collaborator": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}